N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels septic patients

• Autorzy: Piechota M , Banach M. , Irzmanski R. , Misztal M. , Rysz J. , Barylski M. , Piechota-Urbanska M. , Kowalski J. , Pawlicki L.
• Języki publikacji: EN

Abstrakty

EN

The aim of this study was to find the relationship between N-terminal brain natriuretic propeptide (NT-proBNP), procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations in septic patients. This was a prospective study, performed at Medical University Hospital No. 5 in łódź. Twenty patients with sepsis and severe sepsis were included in the study. N-terminal brain natriuretic propeptide, procalcitonin and C-reactive protein concentrations, and survival were evaluated. In the whole studied group (128 measurements), the mean NT-proBNP, procalcitonin and C-reactive protein concentrations were, respectively: 140.80±84.65 pg/ml, 22.32±97.41 ng/ml, 128.51±79.05 mg/l. The correlations for the NT-proBNP level and procalcitonin and C-reactive protein levels were 0.3273 (p<0.001) and 0.4134 (p<0.001), respectively. NT-proBNP levels correlate with PCT and CRP levels in septic patients. In the survivor subgroup, the mean NT-proBNP plasma concentrations were significantly lower than in the non-survivor subgroup.

Słowa kluczowe

EN

procalcitonin; septic patient; human disease; N-terminal brain natriuretic propeptide; relationship; severe sepsis; sepsis; plasma concentration; septic shock; C-reactive protein

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2007
• Tom: 12
• Numer: 2
• Opis fizyczny: p.162-175,ref.

Twórcy

autor

Piechota M

• Medical University of Lodz, Lodz, Poland

autor

Banach M.

autor

Irzmanski R.

autor

Misztal M.

autor

Rysz J.

autor

Barylski M.

autor

Piechota-Urbanska M.

autor

Kowalski J.

autor

Pawlicki L.

Bibliografia

• 1. Members of the American College of Chest Physicians/Society of Crit Care Med Consensus Conference Committee: American College of Chest Physicians/Society of Crit Care Med Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20 (1992) 864-874.
• 2. Ugarte, H., Silva, E., Mercan, D., De Mendonca, A. and Vincent J.L. Procalcitonin as a marker of infection in the intensive care unit. Crit. Care Med. 27 (1999) 498-504.
• 3. Wanner, G.A., Keel, M., Steckholzer, U., Beier, W., Stocker, R. and Ertel, W. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit. Care Med. 28 (2000) 950-957.
• 4. Hoffmann, U., Brueckmann, M., Bertsch, T., Wiessner, M., Liebetrau, C., Lang, S., Haase, K.K., Borggrefe, M. and Huhle, G. Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients. Clin. Lab. 51 (2005) 373-379.
• 5. Castillo, J.R., Zagler, A., Carrillo-Jimenez, R. and Hennekens, C.H. Brain natriuretic peptide: a potential marker for mortality in septic shock. Int. J. Infect. Dis. 8 (2004) 271-274.
• 6. Charpentier, J., Luyt, C.E., Fulla, Y., Vinsonneau, C., Cariou, A., Grabar, S., Dhainaut, J.F., Mira, J.P. and Chiche, J.D. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit. Care Med. 32 (2004) 660-665.
• 7. Witthaut, R., Busch, C., Fraunberger, P., Walli, A., Seidel, D., Pilz, G., Stuttmann, R., Speichermann, N., Verner, L. and Werdan, K. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med. 29 (2003) 1696-1702.
• 8. Nijsten, M.W., Olinga, P., The, T.H., de Vries, E.G., Koops, H.S., Groothuis, G.M., Limburg, P.C., Duis, H.J., Moshage, H., Hoekstra, H.J., Bijzet, J. and Zwaveling, J.H. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit. Care Med. 28 (2000) 586-588.
• 9. Bohuon, C. A brief history of PCT. Intensive Care Med. 26 (2000) 146-147.
• 10. Oberhoffer, M., Vogelsang, H., Jager, L. and Reinhart, K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes. J. Crit. Care 14 (1999) 29-33.
• 11. Gramm, H.J., Beier, W., Zimmermann, J., Oedra, N., Hannemann, L. and Boese-Ladgraf, J. Procalcitonin-A biological marker of inflammatory response with prognostic properties. Clin. Intens. Care 6 (1995) 71.
• 12. Zeni, F., Viallon, A., Assicot, M., Tardy, B., Vindimian, M. and Page, Y. Procalcitonin serum concentrations and severity of sepsis. Clin. Intens. Care 5 (1994) 89-98.
• 13. Hergert, M., Lestin, H.G., Scherkus, M., Brikner, K., Klett, I. and Stranz, G. Procalcitonin in patients with sepsis and polytrauma. Clin. Lab. 44 (1998) 659-670.
• 14. Oberhoffer, M., Biterlich, A., Hentschel, T., Meier-Hellmann, A., Vogelsang, H. and Reinhart, K. Procalcitonin (ProCT) correlates better with the ACCP/SCCM consensus conference definitions than other specific markers of the inflammatory response. Clin. Intens. Care 7 (1996) 46.
• 15. Oberhoffer, M., Vogelsang, H., Rasswurm, S., Hartung, T. and Reinhart, K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin. Chem. Lab. Med. 37 (1999) 363-368.
• 16. Markuszewski, L., Rysz, J., Makowski, M., Debska, A. and Pietruszynski, R. C-reactive protein as a predictor of major adverse cardiac events (MACE) after percutaneous coronary intervention? Arch. Med. Sci. 1 (2005) 152-156.
• 17. Povoa, P., Almeida, E., Moreira, P., Fernandes, A., Mealha, R., Aragao, A. and Sabino, H. C-reactive protein as an indicator of sepsis. Intensive Care Med. 24 (1998) 1052-1056.
• 18. Brueckmann, M., Huhle, G., Lang, S., Haase, K.K., Bertsch, T., Weiss, C., Kaden, J.J., Putensen, C., Borggrefe, M. and Hoffmann, U. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 112 (2005) 527-34
• 19. Chua, G. and Kang-Hoe, L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit. Care 8 (2004) 248-250.
• 20. Piechota, M., Irzmanski, R., Banach, M., Barylski, M., Ostrowski, S., Kowalski, J. and Pawlicki, L. Can impedance cardiography be routinely applied in patients with sepsis and severe sepsis? Arch. Med. Sci. 2 (2006) 114-121.
• 21. Pinilla, J.C., Hayes, P., Laverty, W., Arnold, C. and Laxdal, V. The C-reactive protein to prealbumin ratio correlates with the severity of multiple organ dysfunction. Surgery 124 (1998) 799-805.
• 22. Waydhas, C., Nast-Kolb, D., Trupka, A., Zettl, R., Kick, M., Wiesholler, J., Schweiberer, L. and Jochum, M. Post-traumatic inflammatory response, secondary operations, and late multiple organ failure. J. Trauma 40 (1996) 624-630.
• 23. Rau, B., Steinbach, G., Baumgart, K., Gansauge, F., Grunert, A. and Beger, H.G. Serum amyloid A versus C-reactive protein in acute pancreatitis: clinical value of an alternative acute-phase reactant. Crit. Care Med. 28 (2000) 736-742.
• 24. Castelli, G.P., Pognani, C., Meisner, M., Stuani, A., Bellomi, D. and Sgarbi, L. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit. Care Med. 8 (2004) 234-242.
• 25. Tugrul, S., Esen, F., Celebi, S., Ozcan, P.E., Akinci, O., Cakar, N. and Telci, L. Reliability of procalcitonin as a severity marker in critically ill patients with inflammatory response. Anaesth. Intensive Care 30 (2002) 747-754.
• 26. Hergert, M., Lestin, H.G., Scherkus, M., Brikner, K., Klett, I. and Stranz, G. Procalcitonin in patients with sepsis and polytrauma. Clin. Lab. 44 (1998) 659-670.
• 27. Piechota, M., Banach, M., Irzmanski, R., Barylski, M., Piechota-Urbanska, M., Kowalski, J., Pawlicki, L. Plasma endothelin-1 levels in septic patients. J. Intensive Care Med. 22 (2007), in press.
• 28. Pereira-Barretto, A.C., de Oliveira, M.T., Franco, F.G. and Cassaro-Strunz, C. ProBNP for stratifying patients with heart failure. Arq. Bras. Cardiol. 81 (2003) 239-248.
• 29. Mueller, T., Gegenhuber, A., Poelz, W. and Haltmayer, M. Comparison of the Biomedica NT-proBNP Enzyme Immunoassay and the Roche NTproBNP Chemiluminescence Immunoassay: Implications for the Prediction of Symptomatic and Asymptomatic Structural Heart Disease. Clin. Chem. 49 (2003) 976-979.
• 30. Banach, M., Drozdz, J., Okonski, P. and Rysz, J. Immunological aspects of the statins’ function in patients with heart failure. The raport from the Annual Conference of ESC – Heart Failure 2005. Cell. Mol. Immunol. 2 (2005) 433-437.
• 31. Prontera, C., Emdin, M., Zucchelli, G.C., Ripoli, A., Passino, C. and Clerico, A. Analytical performance and diagnostic accuracy of a fullyautomated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin. Chem. Lab. Med. 42 (2004) 37-44.
• 32. Dahlstrom, U. Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur. J. Heart Fail. 6 (2004) 281-287.
• 33. Irzmanski, R., Banach, M., Piechota, M., Kowalski, J., Barylski, M., Cierniewski, C.S. and Pawlicki, L. Atrial, Brain Natriuretic Peptide and Endothelin-1 concentration in patients with idiopathic arterial hypertension. The dependence on the selected morphological parameters. Clin. Exp. Hypertens. 29 (2007), in press.
• 34. Phua, J., Lim, T.K. and Lee, K.H. B-type natriuretic peptide: issues for the intensivist and pulmonologist. Crit. Care Med. 33 (2005) 2094-2113.
• 35. Ma, K.K., Ogawa, T. and de Bold, A.J. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by proinflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J. Mol. Cell. Cardiol. 36 (2004) 505-513.
• 36. Piechota, M., Irzmanski, R., Banach, M., Kowalski, J. and Pawlicki, L. Impedance cardiography in hemodynamic monitoring of septic patients: prospective study. Arch. Med. Sci. 3 (2007), in press.
• 37. Banach, M. The role of immunological factors in the induction of apoptosis of cardiomyocytes. Drug Pol. 13 (2003) 50-56.